## Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

**BIOMARIN PHARMACEUTICAL INC** Form 4 August 19, 2013 OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... 0.5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person \* 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading **BIENAIME JEAN JACQUES** Issuer Symbol **BIOMARIN PHARMACEUTICAL** (Check all applicable) INC [BMRN] (Last) (First) (Middle) 3. Date of Earliest Transaction \_X\_ Director 10% Owner X\_Officer (give title Other (specify (Month/Day/Year) below) below) C/O BIOMARIN 08/15/2013 Chief Executive Officer PHARMACEUTICAL INC., 105 DIGITAL DRIVE (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) \_X\_ Form filed by One Reporting Person Form filed by More than One Reporting **NOVATO, CA 94949** Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 3. 2. Transaction Date 2A. Deemed 4. Securities Acquired 5. Amount of 6. 7. Nature of Transaction(A) or Disposed of (D) Ownership Indirect Security (Month/Day/Year) Execution Date, if Securities (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially Form: Beneficial anv (Month/Day/Year) (Instr. 8) Owned Direct (D) Ownership Following or Indirect (Instr. 4) Reported  $(\mathbf{I})$ (A) Transaction(s) (Instr. 4) or (Instr. 3 and 4) Code V Amount (D) Price Shares held by Common 08/15/2013 08/15/2013 Bienaime M 1.000 Α \$ 12.99 49.740 I Stock Family Trust<sup>(1)</sup> Shares held \$ by Common 08/15/2013 I Bienaime 08/15/2013 S 1,000 D 64.364 48,740 Stock (2)Family Trust (1)

## Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock						10,000	I	Held in irrevocable trust for Guillaume Bienaime <u>(3)</u>	
Common Stock						10,000	I	Held in irrevocable trust for Pierre Bienaime (3)	
Common Stock						10,000	Ι	Held in irrevocable trust for Paul Bienaime (3)	
Common Stock						10,000	I	Held in irrevocable trust for Marc Bienaime (3)	
Common Stock						20,000	I	Held in irrevocable trust for Aurelie Mitsuki Bienaime and Anais Kimiko (3)	
Reminder: R	eport on a sepa	arate line for each clas	s of securities benefic	Person: informa require	is who respon ation contain ad to respond vs a currently	ndirectly. Ind to the colle ned in this form d unless the for y valid OMB co	n are not rm	SEC 1474 (9-02)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)								
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	Securities	6. Date Exercis Expiration Date (Month/Day/Ye	e	7. Title and A Underlying S (Instr. 3 and	Securities
				Code V	(A) (D)	Date Exercisab	ble Expiration Date	n Title	Amount or Number

					S	Shares
Stock Option (right to buy Common Stock)	\$ 12.99	08/15/2013	08/15/2013	М	1,000 11/11/2006(4) 05/10/2016 Common Stock	1,000

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships					
1 9	Director	10% Owner	Officer	Other		
BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949	Х		Chief Executive Officer			
Signatures						
/s/ Laura Randall Woodhead, Attorney-in-Fact	08/19	9/2013				
**Signature of Reporting Person	D	ate				

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reporting person and his spouse act as trustees for the Bienaime Family Trust.
- The price in column 4 is a weighted average price. The price actually received ranged from \$63.58 to \$65.21. The reporting person will(2) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at eachprice within the range.
- (3) The reporting person's spouse is trustee of each child's trust.
- (4) Original option grant vests 6/48th on November 11, 2006 and 1/48th on the 11th day of every month thereafter.
- (5) Reflects number of stock options outstanding after the transaction from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

of